Additional information
| Active substance | Trastuzumab |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | HER2 testing (immunohistochemistry or fluorescence in situ hybridization) |
| Also known as | rhuMAb HER2 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypertension |
| Trade name | Herceptin |
| Storage conditions | Store refrigerated at 2-8В°C (36-46В°F) |
| Chemical name | Trastuzumab |
| Formula | C6484H9996N1720O2014S44 |
| Substance class | Monoclonal antibody |
| Main action | HER2/neu receptor antagonist |
| Half-life | Approximately 28 days |
| Dosage (medical) | Typically 4 mg/kg as a loading dose followed by 2 mg/kg weekly or 6 mg/kg every three weeks |
| Dosage (sports) | Not applicable |
| Effects | Reduction in tumor growth, improved survival in breast cancer patients |
| Side effects | Fever, nausea, vomiting, infusion reactions, cardiotoxicity |
| Use in sports | None |
| Manufacturer | Roche |
Avory Pharma Oxymethelone 10mg 100 Kapseln
Prograf 1mg Astellas Pharma
Tavanic 500 mg Sanofi
Euthyrox 50 mcg MERC
FACTIVE 320 mg Abdi Ibragim
Rovamycine 3.000.000 iu Eczacibasi
Fostimon (Merional) 150 IU HMG IBSA
Norvacs 10 mg Pfizer
Alpha Pharma Alphabol 10 mg 60 Tabletten
LACIPIL 4 mg Glaxosmithkline 

Reviews
There are no reviews yet.